FL-RAPID-MEDICAL
16.11.2023 16:04:29 CET | Business Wire | Press release
Rapid Medical™, a leading developer of advanced neurovascular devices, announces new data demonstrating excellent first-pass treatment success with the TIGERTRIEVER™ device in complex ischemic stroke patients with underlying intracranial atherosclerotic disease (ICAD). The complication rates were negligible, as reported at the 2023 Society of Vascular and Interventional Surgery’s (SVIN) Annual Meeting.
“Patients with ICAD experiencing a stroke are very challenging to treat and often need rescue therapy such as stenting,” states Dr. Edgar Samaniego, Endovascular Neurologist at the University of Iowa and lead author. “We achieved very high treatment success and lasting results with TIGERTRIEVER alone that we haven’t seen with other devices. We attribute this to TIGERTRIEVER’s unique ability to open and dilate these blocked vessels, a new term we call stentplasty.”
As published in the Journal of NeuroInterventional Surgery, this sub-analysis of the prospective TIGER trial1 showed that 78% of ICAD patients achieved successful reperfusion without further intervention; 47% achieved recanalization on the first pass.2 These results are significantly better than studies utilizing other devices in this unique patient population. Moreover, TIGERTRIEVER in ICAD rivals the results only thought possible in non-ICAD patients. Another benefit of the high first-pass success rates was very fast procedure times; the groin to revascularization 22-minute median is the fastest reported in any prospective, randomized trial. It is worth noting that 50% of these patients had a good clinical outcome defined as mRS 0-2 at 90 days.
Unlike conventional stent retrievers, the TIGERTRIEVER device offers the distinctive capability to control radial expansion after it is positioned in a brain artery, providing exclusive advantages for ICAD patients. In addition to successful reperfusion, TIGERTRIEVER significantly dilated the artery such that no patient required permanent stenting. Furthermore, patients included in the study did not suffer symptomatic intracranial hemorrhage (sICH), vessel dissection, or embolic complications–typically more frequent in these ICAD patients– since the device can also be contracted to minimize disruption to the plaque and arteries during removal.
“Physicians now have a better and faster treatment option for patients with severely narrowed, stenotic arteries,” continues Dr. Samaniego. “TIGERTRIEVER provides a higher rate of successful reperfusion, reduced complications, and a needed angioplasty-like effect compared with historical studies that utilized other mechanical thrombectomy devices.”
For more information about the study, please refer to the published article in the Journal of NeuroInterventional Surgery: https://jnis.bmj.com/content/early/2023/09/29/jnis-2023-020796
About Rapid Medical
Rapid Medical expands what’s possible in neurovascular treatment by pioneering advanced interventional devices to treat ischemic and hemorrhagic stroke. Utilizing proprietary manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the anatomy and tailor the approach to every patient for better procedural outcomes. TIGERTRIEVER™ 13, 17 and 21, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER XL is also CE marked. More information is available at www.rapid-medical.com
________________________
1 Gupta R, Saver JL, Levy E, et al. New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial [published correction appears in Stroke. 2021 Jun;52(6):e310]. Stroke. 2021;52(5):1534-1544. doi:10.1161/STROKEAHA.121.034436
2 Ojeda DJ, Ghannam M, Sanchez S, et al. Tigertriever in the treatment of acute ischemic stroke with underlying intracranial atherosclerotic disease [published online ahead of print, 2023 Sep 30]. J Neurointerv Surg. 2023;jnis-2023-020796. doi:10.1136/jnis-2023-020796
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116284748/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paymentology Raises $175 Million co-led by Apis Partners and Aspirity Partners to Support Next Phase of Growth12.5.2026 09:01:00 CEST | Press release
Paymentology, the leading global issuer-processor, today announced a $175 million investment co-led by Apis Partners (”Apis”), a private equity firm specialising in financial infrastructure and services, and Aspirity Partners (“Aspirity”), a pan-European Private Equity firm focused on Financial Technology & Services and Enterprise Technology & Connectivity Services. The investment will support Paymentology’s continued global expansion, product development and strengthening of its team, as the company builds on strong demand for modern issuer processing on a global scale. The transaction brings together two investors with deep experience in the payments industry and a shared focus on advancing payments infrastructure, united by the view that issuer processing represents one of the most significant opportunities in the sector. For Apis, the investment, made by Apis Growth Fund III1, marks the firm’s 16th payments investment. Both Apis and Aspirity will draw on their deep sector and globa
IQM Launches HPC Integration Service to Accelerate Hybrid Quantum-HPC Adoption12.5.2026 09:00:00 CEST | Press release
IQM Radiance systems now operate as computational nodes inside HPC environments. The hybrid workflows are scheduled and managed alongside CPUs and GPUs by the same workload manager already operational in the world’s top supercomputing centers. The new HPC Integration Service reflects the company’s production quantum model – end-users own the hardware, run it on their infrastructure, and operate it under their control. IQM Quantum Computers today launched HPC Integration Service, a turnkey solution that enables its IQM Radiance quantum computers to operate as a slurm node inside high-performance computing (HPC) environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512187465/en/ IQM Radiance quantum computer (right) co-located with classical HPC infrastructure (left) in a data center environment. Using this widely adopted HPC workflow, IQM aims at accelerating adoption of hybrid quantum-classical computing across ente
Visa Flexible Credential Brings More Flexible Ways to Pay to Zilch Cardholders in the UK12.5.2026 09:00:00 CEST | Press release
Visa, Zilch and Thredd collaborate to help issuers deliver a simpler, more flexible card experience for users. Visa, a world leader in digital payments, Zilch and Thredd today announced the introduction of Visa Flexible Credential (VFC) on Zilch cards in the UK, enabling more flexible ways to pay through a single, familiar card experience. Demand for flexible payment experiences continues to grow. Many people no longer think in fixed terms such as debit or credit, instead wanting the ability to choose what works best for a specific purchase in the moment. In the UK, 87% of people surveyed say flexible payment options support their financial or lifestyle goals1. Visa Flexible Credential is designed to support this shift, helping issuers offer more choice through one familiar card that already works at more than 150 million merchant locations worldwide. The new capability allows different payment options to sit behind one card or digital credential, giving cardholders greater choice and
AMP IT Announces New Funding Round to Scale Its Private EV Charging as a Service in Switzerland and Beyond12.5.2026 08:43:00 CEST | Press release
AMP IT, a Geneva-based energy and mobility company, today announced the successful completion of a new funding round to accelerate the deployment of its private EV charging and energy management platform across Switzerland and international markets. Founded in 2021, AMP IT develops, finances, installs, and operates smart EV charging infrastructure for residential buildings, commercial real estate, and corporate fleets. Through its charging-as-a-service model, the company combines infrastructure with its proprietary software, AMP IT Hub, delivering a fully integrated energy solution. The latest funding round, supported notably by the Swiss Technology Fund, brings AMP IT’s total funding to €7 million since inception. The capital will support operational scaling, further development of its software platform, and expansion into selected European markets. “Users are increasingly looking for solutions that are simple, efficient, and affordable which is exactly what we provide,” said Florian
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 08:30:00 CEST | Press release
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom